skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

19 Total results for product and free and sample content found

Datamonitor Healthcare

Profitability Assessment of Branded Generic Inhalers

By Ljlal Syed, Mark Lansdell and David Abramson 28 Jul 2022

Profitability Assessment of Branded Generic Inhalers

This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic

Topic Deals

Generics Bulletin

Pfizer Reports 80% Biosimilars Growth In Q3

By Akriti Seth 17 Nov 2020

pfizer biosimilars growth

Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

Topic Coronavirus Biosimilars Deals

Scrip

2020’s Most Significant Cancer Deals

21 Oct 2020

2020’s Biggest Deals at a Glance

Gain insights into the oncology deals making headlines with exclusive reporting and analysis from Scrip. Explore a snapshot view of the year’s biggest oncology deals so far, in a convenient infographic and go deeper into two major cancer deals that occurred in September with your free article pack.    

Topic Cancer Deals

In Vivo

In Vivo Deal Making Article Pack

15 Apr 2020

In Vivo Deal Making Article Pack

Gain a view into the market gaps, opportunities, and trends in biopharma with a look at deal-making from In Vivo. Examine how deal-making has impacted the industry and shifted market dynamics and learn how you can use knowledge of these trends to inform your own strategies.

Topic M A Deals

Scrip

J.P. Morgan 2020: What To Watch For At The Industry's Biggest Meeting

By Jessica Merrill 08 Jan 2020

JP_Morgan_2020_What_To_Watch

The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.

Topic Deals Leadership M A

Scrip

Novartis Sees Reimbursement Advantage For PCSK9 Launch

By Jessica Merrill 28 Nov 2019

Analysis

Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.

Topic Business Strategies Deals Reimbursement

Generics Bulletin

Lupin Offloads Kyowa For $525m But Not Exiting Japan

By Vibha Ravi 13 Nov 2019

Analysis

Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.

Topic Deals Strategy

MS Outlook 2020 Scrip 100

24 Jul 2019

MS Outlook 2020 Scrip 100

Outlook 2020 is the annual look at the performance and future prospects of the global pharmaceutical industry. This year, the supplement will reach more people than ever before with distribution to In Vivo, Pink Sheet, Scrip, Medtech Insight and Generics bulletin subscribers PLUS events such as Biotech Showcase and Partnerships in Clinical Trials.

Topic Deals BioPharmaceutical Business Strategies

Pink Sheet

The Drug Pricing Article Pack

15 Jul 2019

The Drug Pricing Article Pack

Get expert insights into the events driving drug pricing polices around the world.  This Article Pack covers drug pricing issues for: The EU - Vital developments for Norway, Denmark, and other EU countries, including the UK The US – Essential drug pricing info from a country where the issue has taken center stage Australia – Developments surrounding drug pricing issues in Australia

Topic Deals Policy & Regulation

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: